Robert E. Landry - 23 Jan 2024 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
EVP Finance CFO
Signature
/s/**Robert E. Landry
Issuer symbol
REGN
Transactions as of
23 Jan 2024
Net transactions value
-$464,512
Form type
4
Filing time
25 Jan 2024, 16:17:25 UTC
Previous filing
18 Jan 2024
Next filing
02 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Options Exercise $416,878 +1,100 +4.8% $378.98 24,084 23 Jan 2024 Direct
transaction REGN Common Stock Tax liability $736,036 -776 -3.2% $948.50 23,308 23 Jan 2024 Direct
transaction REGN Common Stock Options Exercise $189,490 +500 +2.1% $378.98 23,808 24 Jan 2024 Direct
transaction REGN Common Stock Tax liability $334,844 -352 -1.5% $951.26 23,456 24 Jan 2024 Direct
holding REGN Common Stock 270 23 Jan 2024 By 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -1,100 -7.8% $0.000000 13,087 23 Jan 2024 Common Stock 1,100 $378.98 Direct F1
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -500 -3.8% $0.000000 12,587 24 Jan 2024 Common Stock 500 $378.98 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option award vests in four equal annual installments, commencing one year after the date of grant.